To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension
Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the change from baseline in systolic blood pressure between KN060 and placebo in patients with essential hypertension over 12 weeks; the secondary objectives are to assess the safety and tolerability of KN060 and to assess the pharmacokinetic and pharmacodynamic properties and immunogenicity of KN060 in patients with essential hypertension.
The main questions it aims to answer are:
* To verify the efficacy of KN060 in patients with essential hypertension
* Safety of KN060 in Subjects Treated for Essential Hypertension Researchers will compare KN060 to placebo (0.9% sodium chloride 100ml) to assess the antihypertensive effect of KN060.
Subjects will :
* Receive KN060 or placebo by intravenous drip every two weeks for 6 doses.
* AOBP, 24hABPM, HBPM,and safety were monitored and recorded.